Migraine. Migraine
Conditions
Interventions
Intervention 1: Intervention group: Zinc Gluconate tablets, 15 mg, daily, orally for 12 weeks. Intervention 2: Intervention group: Placebo tablets, 15 mg, daily, orally for 12 weeks.
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Age range 18-55 years female Resident of Urmia Having episodic or chronic migraines Interested in collaborating in the study with a 3-month intervention
Exclusion criteria
Exclusion criteria: Use of any supplement or multivitamin - mineral in the last 3 months Pregnancy Breastfeeding smoking History of serious head trauma or head and neck surgery in the past 2 years A history of vasculitis Malignancies AIDS History of diabetes History of stroke and coronary artery disease Cardiovascular disease Asthma Rheumatoid Arthritis Kidney or liver failure kidney stone Use of drugs that decrease lipid profile (total cholesterol, TG, LDL-C) Taking non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen (for more than 15 days per month in the last 3 months) History of mental disorders such as depression blood pressure Digestive diseases 21. Lupus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of migraine attacks. Timepoint: At baseline (before intervention) and 30, 60, and 90 days after starting zinc gluconate supplementation. Method of measurement: Monthly Notepad.;The severity of migraine attacks. Timepoint: At baseline (before intervention) and 30, 60 and 90 days after zinc gluconate supplementation. Method of measurement: Pain severity questionnaire NRS (Numeric Rating Scale).;The period of migraine attacks. Timepoint: At baseline (before intervention) and 30, 60 and 90 days after zinc gluconate supplementation. Method of measurement: Monthly Notepad. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum level of zinc. Timepoint: At baseline (before intervention) and 90 days after zinc gluconate supplementation. Method of measurement: dialab kit of zinc.;Serum cholesterol level. Timepoint: At baseline (before intervention) and 90 days after zinc gluconate supplementation. Method of measurement: pars azmun kit.;Serum triglyceride levels. Timepoint: At baseline (before intervention) and 90 days after zinc gluconate supplementation. Method of measurement: pars azmun kit.;Serum level of Low Density Lipoprotein (LDL). Timepoint: At baseline (before intervention) and 90 days after zinc gluconate supplementation. Method of measurement: pars azmun kit.;Serum level of High Density Lipoprotein (HDL). Timepoint: At baseline (before intervention) and 90 days after zinc gluconate supplementation. Method of measurement: pars azmun kit.;Serum level of high sensitivity C-Reactive Protein (hs-CRP). Timepoint: At baseline (before intervention) and 90 days after zinc gluconate supplementation. Method of measurement: pars azmun kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRasoul Zarrin
Oroumia University of Medical Sciences
Outcome results
None listed